Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA approves Bavencio for metastatic Merkel cell carcinoma

March 24, 2017

ImmunoCellular Therapeutics and Memgen sign immuno-oncology collaboration letter of intent

March 24, 2017

BioLineRx acquires Agalimmune

March 24, 2017

Cue Biopharma selects lead candidate Cue-101 targeting HPV-associated cancers

March 23, 2017

Preliminary results from malignant pleural mesothelioma cohort of KEYNOTE-028 study

March 23, 2017

Heat Biologics reports phase II interim data on HS-110 with nivolumab in NSCLC

March 22, 2017

New phase I/II trial explores use of APX-005M with pembrolizumab in metastatic melanoma

March 22, 2017

Pierre Fabre and H-Immune establish research partnership in cancer immunotherapy

March 22, 2017

FDA grants orphan drug designation to NantKwest's activated natural killer cell therapy

March 22, 2017

EURE-CART project holds launch meeting

March 21, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...